CAMBRIDGE, Mass., Nov. 8 /PRNewswire/ -- Cytel Inc., the leader in clinical trial design software and services, announced today the version 7 release of StatXact(R) and LogXact(R). Both releases deliver high degrees of new user-requested features and important statistical methodology innovations.
With new StatXact(R) 7, users can perform test of correlation across a single variable, compute p-value for the test of trend in multiple outcomes, estimate conditional maximum likelihood of trend parameters in correlated data, as well as conduct clustered response tests for correlation significance.
LogXact(R) 7 is now able to conduct missing value analysis for Logit, Probit, Cloglog, Poisson and Normal regression. Cytel developers have incorporated Firth’s penalized maximum likelihood estimates -- a major improvement in logistic regression modeling. These estimates correct for bias and also exhibit mean square error lower than the usual maximum likelihood estimates for most data that arise in practice.
“Our new releases not only expand statistical computing capability, but also provide string operations, better batch language, new graphics and visual aids through Cytel Studio.” said Nitin Patel, Cytel’s Chairman and Co-Founder. “By delivering ever more advanced compute power and functionality, StatXact(R) and LogXact(R) continue as the world’s most comprehensive exact statistics and logistic regression analysis applications.”
Availability and Platforms
StatXact(R) 7 and LogXact(R) 7, with Cytel Studio are available today for Windows NT/2000/XP.
For SAS statistical applications users, Cytel offers StatXact 7 PROCs and LogXact 7 PROCs, making available all the new releases’ advanced features from within their SAS environment.
For more information, including real-world data examples, and a 30 day free trial version go to www.cytel.com, call 617-661-2011, or inquire via info@cytel.com.
About Cytel Inc.
Cytel Inc. has an 18-year track record as the premier provider of software and services for the design and analysis of clinical trials. Cytel provides software, training, and consulting to clinical trial sponsors seeking greater efficiency. Cytel’s East(R) is used by every FDA division, and hundreds of biostatisticians and clinicians in industry and academia to design, simulate and monitor group sequential and adaptive flexible clinical trials. Over 10,000 customers also use Cytel’s award-winning StatXact(R) and LogXact(R) software for exact statistical inference. Cytel Inc. is a privately owned company, with venture capital investment, headquartered in Cambridge, Massachusetts, and development operations in Pune, India.
Cytel Inc.
CONTACT: Michael Weitz of Cytel Inc., +1-617-528-7132
Web site: http://www.cytel.com/